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INTRODUCTION
Gianotti-Crosti syndrome (GCS) is a disease of self-limit-
ed acrolocated eruption characterized by acute onset of sym-
metrical papules over the limbs and face, which may last up
to 8 weeks (1). This syndrome is frequently associated with
hepatitis B (HB) antigenemia (2), but hepatitis B virus (HBV)
antigen-negative cases had been subsequently described by
Gianotti (2). A wide spectrum of viral diseases and preced-
ing immunizations are associated with the disease (3, 4). 
We report a case of GCS following Japanese encephalitis
(JE) vaccination. To our knowledge, this is the first case of GCS
associated with Japanese encephalitis vaccine.
CASE REPORT
A three-year-old Korean boy presented with pruritic rashes
for 1 week. He was generally healthy and vaccinated against
JE 1 day before developing cutaneous manifestations. No
drug history was found. Physical examination revealed sym-
metrical erythematous macules and papules on his face, trunk,
and extremities (Fig. 1). Concomitant lymphadenopathies
of right postauricular, right axillar, and both inguinal areas
were detected. Complete blood cell count was normal except
moderate eosinophilia (7.2%). Other laboratory examinations
including liver function test, urinalysis and chemical profiles
were normal. Skin biopsy from right upper arm revealed focal
spongiosis with mild lymphocytic exocytosis in epidermis.
Mild superficial and deep perivascular inflammatory infil-
trates composed of lymphocytes were noted in dermis (Fig. 2). 
Under the impression of GCS, further evaluations were
performed to reveal viral etiology. Serum hepatitis B surface
antigen (HBsAg) was negative and antibody to HbsAg
(HBsAb) was positive due to the routine scheduled vaccina-
tion. Serum JE antibody was positive (1:40) by hemagglu-
tinin inhibition (HI) test. His symptoms were all cleared 2
weeks after conservative antihistamine treatment.
DISCUSSION
GCS shows characteristic cutaneous eruption following
viral infection or immunization (1). Although HBV is the
most common etiologic agent (5), it is now generally accept-
ed that GCS can be triggered by a variety of other viruses,
such as Epstein-Barr virus (6), poxvirus (7), parvovirus B19
(7), human herpes virus 6 (8), rotavirus (9), HIV (10), and
CMV (11). It is also associated with vaccinations against
influenza virus (12), diphtheria (6), pertussis (6), poliovirus
(6), measles, mumps, or rubella (MMR) (4). 
The precise pathogenic mechanism of GCS remains unclear
until now. Caputo et al. suggested that GCS is a self-limiting
cutaneous response to different viruses; clinical differences
are probably due to individual characteristics of each patient
rather than the causative virus (13). However, Drijkoningen
et al. suggested that inflammatory infiltrates consisting of
dendritic cells and T cells in the skin and around the small
vessels in GCS are similar to the reactive lymph node (14).
The latter can be correlated with the dendritic cell-T cell
clusters of the primary immune response observed in vitro
(14). This delayed type of T cell immune response can be
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We report a three-year-old Korean boy who presented with itching symmetrical
erythematous macules and papules on his face, trunk, and extremities for 1 week.
Lymphadenopathies were detected on physical examination. He was vaccinated
against Japanese B Encephalitis (JE) 1 day before developing skin rashes. The
patient’s serum JE antibody titer by hemagglutinin inhibition (HI) test was 1:40.
Under the diagnosis of Gianotti-Crosti syndrome following JE vaccination, he was
conservatively treated with an antihistamine agent, and his symptoms were all
cleared 2 weeks after treatment.
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induced by a number of chemical and physical stimuli or
pathogens. In this regard, Magyarlaki et al. suggested virus-
induced type IV cutaneous hypersensitivity (15).
Mostly, GCS is diagnosed by clinical manifestations with
specific viral etiology. In our case, physical examination re-
vealed characteristic symmetrical erythematous macules and
papules with concomitant lymphadenopathies. His symp-
toms developed after the first immunization against JE.
Inactivated JE virus suspension from infected mouse brain
is used for JE immunization in Korea, Japan, and U.S.A. In
case of suspicious JE infection, HI test is firstly indicated.
Our patient’s serum JE antibody titer was 1:40. Following
JE vaccination, antibody titer higher than 1:10 indicates
successful immunization. If antibody titer is 1:80 or higher,
recent JE infections is suspected rather than vaccination and
ELISA test to JE antibody is recommended to confirm active
JE infection. Hence the HI test titer 1:40 in our patient was
considered to result from JE vaccination.
JE is a viral zoonosis spread by Culex mosquitoes in most
Asian countries (16). According to the Korean Ministry of
Health and Welfare, the estimated coverage rate of this immu-
nization is over 95%. Vaccination against JE is recommend-
ed for children aged 3 to 15 yr. The interval of booster vac-
cination schedule for JE has been changed from every other
year to only twice (6th and 12th year) since 2000. 
In this case, further recommendation of booster JE vacci-
nation depends on the physician according to the JE preva-
lence of the area. Studies in the United Kingdom and the
United States found that, after two doses, fewer than 80%
of patients produced neutralizing antibody. The percentage
substantially declined to less than 29% following 6 to 12
months (17). After three doses, 90% produced the antibody
(18).
Recently, a few studies on the side effects after JE immu-
nization have been conducted. The side effects are cutaneous,
respiratory, cardiovascular, and neurologic symptoms. These
symptoms are rare but have been reported by several nations
among travelers from Europe, North America, and Australia
(19-22). According to a Japanese report, two patterns of
systemic immediate type reaction to JE vaccine exist (16).
One is associated with cutaneous and respiratory symptoms,
and the other with cardiovascular symptom. Cutaneous side
Fig. 1. Clinical photography showing multiple acrolocated erythe-
matous macules and papules. (A) on the right upper arm. (B) on
both dorsum of hands. A
B
Fig. 2. Focal spongiosis with mild lymphocytic exocytosis in epi-
dermis. Mild superficial and deep perivascular inflammatory infil-
trates composed of lymphocytes in dermis (H&E stain,  40).Gianotti-Crosti Syndrome 461
effects are urticaria, angioedema or itching (16). Interest-
ingly, more than half of the cases revealed delayed onset of
1-3 days, and these are the hallmark of the hypersensitivity
reactions associated with JE vaccination. The incidence of
cutaneous reactions is 15-18 per 10,000 vaccinees (23). 
We herein described a patient of GCS following immu-
nization against JE with literature review. Our case repre-
sents one of the dermatologic side effects following JE vac-
cination.
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